saracatinib

Term ID

CHEBI:47458

Synonyms

AZ-10353926
AZD 0530
AZD-0530
AZD0530
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
N-(5-chloro-2H-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine
saracatinib
saracatinibum

Definition

A member of the class of quinazolines that is quinazoline substituted by (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy and 2-(4-methylpiperazin-1-yl)ethoxy groups at positions 4, 5 and 7, respectively. It is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). Saracatinib was originally developed by AstraZeneca for the treatment of cancer but in 2019 it was granted orphan drug designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs.

References

Ontology

ChEBI ( EBI )

Relationships

is a type of: aromatic ether benzodioxoles diether N-methylpiperazine organochlorine compound ... Show All 8 Terms

aromatic ether benzodioxoles diether N-methylpiperazine organochlorine compound oxanes quinazolines secondary amino compound Show first 5 Terms
has_role: anticoronaviral agent antineoplastic agent apoptosis inducer autophagy inducer EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor ... Show All 6 Terms

anticoronaviral agent antineoplastic agent apoptosis inducer autophagy inducer EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor radiosensitizing agent Show first 5 Terms

Phenotype

Phenotype resulting from saracatinib

Phenotype where environments contain saracatinib

Phenotype modified by environments containing saracatinib

Human Disease / Model Data

Citations